Views & Analysis | Perspectives on pharma industry issues

R&D

Representation of bipolar and other mental health disorders, Janus concept

The role of the opioid pathway in schizophrenia and bipolar ...

Psychiatry has spent decades focused on dopamine, serotonin, norepinephrine, and glutamate.

Digital

Man shakes woman's hand in signal of a business deal

Changing Faces: Digital and supplier, January 2026

The life sciences supplier and digital health sectors witnessed significant leadership movements in January.

R&D

steaming nebulizer mask in hand instructing African American daughter

Advancing RSV and hMPV research through human challenge tria...

Human challenge trials offer a complementary approach, and hVIVO has been at the forefront of this field for decades.

Patients

Interview at JPM26 with Alexander Schneider

New hope for ovarian cancer, with Alexander Schneider

Alexander Schneider, CEO of CureLab Oncology, shares how his company’s drug candidate for platinum-resistant ovarian cancer is named after his wife.

Sales & Marketing

Swiss train speeding across bridge against landscape background

A fast start to 2026 signals continued investor confidence i...

Key factors in Switzerland’s success that could make other European life sciences hubs more attractive to investors.

R&D

Three scientists discuss a grant application

What to do when your grant application fails

All hope should not be lost and an unsuccessful application doesn’t always mark the end of the road.

R&D

Post-hype, pre-value: The real AI-pharma shift starts now

The first era of AI in pharma was built on potential. This next era will be built on proof, reinforcing even greater potential.

Digital

Interview at Hlth 2025 with Dr Adam Brow

Chaos & opportunity: Dr Adam Brown unpacks US health policy

Dive into our video interview with Dr Adam Brown as he unpacks the chaos and opportunity shaping US health policy.

Sales & Marketing

A fast start to 2026 signals continued investor confidence i...

Key factors in Switzerland’s success that could make other European life sciences hubs more attractive to investors.

Sales & Marketing

Woman shakes man's hand in hiring process

Changing Faces: Agency and consultancy, January 2026

The pharmaceutical services sector saw a flurry of new executive hires last month, spanning agencies, consultancies, investment firms & a few others.

Digital

Changing Faces: Digital and supplier, January 2026

The life sciences supplier and digital health sectors witnessed significant leadership movements in January.

Digital

From engagement metrics to meaningful experience: Why pharma...

Pharma digital success still focuses on clicks and downloads, but true performance is whether content actually meets real end-user needs

Market Access

Biotech leaders: ‘They're shoving this industry into the arm...

At the Biotech Showcase during JPM Week, biotech leaders expressed frustration at the US's lack of concern about Chinese biotech progress.

Market Access

European biopharma at a crossroads

If Europe can bridge its operational gaps while leveraging its scientific base, it can carve out a distinctive and sustainable leadership position.

Oncology

A cancer treatment modality that prioritises QoL, with Ben Z...

Immuneering's Ben Zeskind explains how, by focusing on quality of life as well as quantity, they've created a drug for pancreatic cancer.

Oncology

Improving breast cancer outcomes in sub-Saharan Africa

New funding from The Pfizer Foundation will support breast cancer efforts in Kenya by the Academic Model Providing Access to Healthcare (AMPATH).

Oncology

Engineering “smarter” cells, with Tim Lu

Senti Bio's Tim Lu discusses “logic-gated” cells, which have multiple receptors allowing them to attack cancer cells while leaving healthy cells alone

Patients

New hope for ovarian cancer, with Alexander Schneider

Alexander Schneider, CEO of CureLab Oncology, shares how his company’s drug candidate for platinum-resistant ovarian cancer is named after his wife.

Patients

Patient centricity: How pharma can move beyond the buzzwords

One important way that pharma companies can deliver true patient advocacy is by bringing cross-functional experience to the table.

Patients

Precision medicine in action, with Cary Claiborne

Cary Claiborne, CEO of Adial Pharmaceuticals, discusses his company’s bet on a precision treatment for AUD.

The role of the opioid pathway in schizophrenia and bipolar ...

Changing Faces: Digital and supplier, January 2026

Advancing RSV and hMPV research through human challenge tria...

New hope for ovarian cancer, with Alexander Schneider

A fast start to 2026 signals continued investor confidence i...

What to do when your grant application fails

Post-hype, pre-value: The real AI-pharma shift starts now

Chaos & opportunity: Dr Adam Brown unpacks US health policy

A fast start to 2026 signals continued investor confidence i...

Changing Faces: Agency and consultancy, January 2026

Changing Faces: Digital and supplier, January 2026

From engagement metrics to meaningful experience: Why pharma...

Biotech leaders: ‘They're shoving this industry into the arm...

European biopharma at a crossroads

A cancer treatment modality that prioritises QoL, with Ben Z...

Improving breast cancer outcomes in sub-Saharan Africa

Engineering “smarter” cells, with Tim Lu

New hope for ovarian cancer, with Alexander Schneider

Patient centricity: How pharma can move beyond the buzzwords

Precision medicine in action, with Cary Claiborne

The role of the opioid pathway in schizophrenia and bipolar ...

Advancing RSV and hMPV research through human challenge tria...

Best practices in cardiometabolic trial design: Planning and...

Report says Jim O'Neill's time at HHS is nearing its end

How to meet your physicians where they are online

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks